Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Icon Plc (ICLR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 7,266,656
  • Shares Outstanding, K 53,971
  • Annual Sales, $ 2,596 M
  • Annual Income, $ 322,660 K
  • 60-Month Beta 0.66
  • Price/Sales 2.75
  • Price/Cash Flow 17.38
  • Price/Book 5.27

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate 1.62
  • Number of Estimates 8
  • High Estimate 1.70
  • Low Estimate 1.54
  • Prior Year 1.42
  • Growth Rate Est. (year over year) +14.08%

Price Performance

See More
Period Period Low Period High Performance
1-Month
127.58 +4.94%
on 03/08/19
147.31 -9.12%
on 02/25/19
-11.17 (-7.70%)
since 02/15/19
3-Month
118.10 +13.36%
on 01/03/19
147.31 -9.12%
on 02/25/19
+3.44 (+2.64%)
since 12/18/18
52-Week
110.21 +21.48%
on 04/04/18
155.33 -13.81%
on 10/01/18
+11.67 (+9.55%)
since 03/16/18

Most Recent Stories

More News
ICON Wins Multiple Categories in 2019 CRO Leadership Awards

ICON plc, (NASDAQ: ICLR) a global provider of drug development and commercialisation services to the pharmaceutical, biotechnology and medical device industries, has won awards across several...

ICLR : 133.88 (-0.56%)
Report: Developing Opportunities within Amazon, Prospect Capital, Alliance Data, Duke Realty, Stellus Capital Investment, and ICON -- Future Expectations, Projections Moving into 2019

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Amazon.com, Inc. (NASDAQ:AMZN),...

ADS : 171.78 (-0.37%)
ICLR : 133.88 (-0.56%)
PSEC : 6.62 (+0.76%)
DRE : 30.34 (-0.75%)
SCM : 14.09 (+0.64%)
AMZN : 1,742.15 (+1.74%)
MolecularMD is acquired by ICON

MolecularMD Corporation, a molecular diagnostic specialty laboratory that enables the development and commercialisation of precision medicines in oncology, announced today that it has been acquired by...

ICLR : 133.88 (-0.56%)
Icon PLC (ICLR) Beats Q4 Earnings and Revenue Estimates

Icon PLC (ICLR) delivered earnings and revenue surprises of 1.25% and 0.47%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

ICLR : 133.88 (-0.56%)
Icon PLC: 4Q Earnings Snapshot

DUBLIN (AP) _ Icon PLC (ICLR) on Wednesday reported fourth-quarter earnings of $88.2 million.

ICLR : 133.88 (-0.56%)
ICON Reports Fourth Quarter and Full Year 2018 Results

--Record net business wins* in the quarter of $607 million, a book to bill of 1.25. Full year net business wins* of $2.4 billion, a net book to bill of 1.27.

ICLR : 133.88 (-0.56%)
PFE : 41.81 (+0.07%)
Icon PLC (ICLR) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Icon PLC (ICLR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ICLR : 133.88 (-0.56%)
ICON Launches New Drug Safety Reporting Solution that Ensures Compliance through Automation

ICON plc, (NASDAQ: ICLR) a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced the release of a...

ICLR : 133.88 (-0.56%)
ICON Issues Financial Guidance for Full Year 2019

--Full Year 2019 Revenue guidance in the range of $2,735 - $2,835 million, representing growth of 5.2 - 9.0%.

ICLR : 133.88 (-0.56%)
AMN or ICLR: Which Is the Better Value Stock Right Now?

AMN vs. ICLR: Which Stock Is the Better Value Option?

AMN : 46.25 (-0.62%)
ICLR : 133.88 (-0.56%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

See More Share

Trade ICLR with:

Business Summary

ICON plc is a global full service clinical research organisation. The company provides contract clinical research services to the pharmaceutical industry worldwide.

See More

Key Turning Points

2nd Resistance Point 136.43
1st Resistance Point 135.16
Last Price 133.88
1st Support Level 132.20
2nd Support Level 130.51

See More

52-Week High 155.33
Fibonacci 61.8% 138.09
Last Price 133.88
Fibonacci 50% 132.77
Fibonacci 38.2% 127.45
52-Week Low 110.21

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar